Printer Friendly

Theregen Company Receives $1.5 Million From Sanderling Ventures to Conduct Anginera(TM) Phase I Clinical Development.

SAN FRANCISCO -- Theregen Company, a regenerative medicine company, has received $1.5 million from Sanderling Ventures to fund clinical development of Anginera(TM), its lead heart therapy product.

The U.S. Food and Drug Administration has approved Theregen's Investigational New Drug (IND) application to conduct a Phase I safety trial of Anginera in patients with acute myocardial ischemia. Theregen plans to initiate the Phase I study in early 2006.

"We are pleased that Sanderling Ventures, a highly regarded venture capital investment firm, recognizes the compelling scientific basis and market potential of Anginera," said Thomas A. Schreck, Chief Executive Officer of Theregen. Sanderling has purchased $1.5 million of Series A Preferred stock from Theregen. Sanderling will close a second round of funding as Theregen achieves specified development milestones. Timothy C. Mills, Ph.D., Managing Director from Sanderling Ventures, joins the company's Board of Directors as its Executive Chairman. "The Theregen technology represents great promise in providing a unique treatment option for patients with cardiovascular disease," said Dr. Mills.

Theregen Company (www.theregencompany.com) is a regenerative medicine company that develops cell-based therapies for cardiovascular and vascular indications. Theregen's lead product, Anginera, is being developed to treat diffuse small vessel disease associated with myocardial ischemia. The product is an epicardial, cell-based therapy designed to promote angiogenesis and arteriogenesis (blood vessel formation) in ischemic areas of the human heart.

"We have assembled outstanding teams of scientific and clinical advisors to help direct us through the next several years of research planning and clinical development," said Theregen President and co-founder Michael Siani-Rose.

Theregen is located in San Francisco, Calif., with research and development facilities in Tucson, Ariz.

Sanderling Ventures, San Mateo and La Jolla, Calif., is a life science venture capital firm that focuses on promising, early stage healthcare technologies. Founded in 1979, Sanderling has demonstrated that significant companies are best built in close working partnerships with entrepreneurs.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jan 17, 2006
Words:315
Previous Article:Intalio Adds Celequest BAM Technology to Its BPMS Solution; Celequest Process Management Dashboards Integrated Into Intalio/BPMS.
Next Article:Longview Fibre to Webcast Fourth Quarter and Full Fiscal Year 2005 Earnings Conference Call Wednesday, January 18, 2006.
Topics:


Related Articles
ChemoCentryx Raises $33 Million in Private Financing.
Zelos Therapeutics Raises $42.5 Million Financing; Company Reports Progress for Two Clinical Programs.
Triage Wireless Secures $3M Series A Investment Led by Sanderling and 3i; Company's Wireless Technology Improves Accuracy in Monitoring Vital Signs /...
Aerie Pharmaceuticals Announces $21 Million Series A Financing; Company to Develop Innovative Products for Treatment of Glaucoma.
Light Sciences Oncology Completes Second Closing in $67 Million Financing for Late Stage Development of Litx(TM) and Announces Additional Directors;...
Theregen Announces Equity Investment from Guidant Corporation to Develop Anginera(TM) Epicardial Patch.
Theregen's Heart Patch of Living Cells Successfully Placed on First Patient.
IDM Pharma Appoints Edward E. Penhoet, Ph.D to Board of Directors.
ProCertus BioPharm, Inc. Closes $2.3 Million Series A Financing Led by Venture Investors LLC.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters